Leerink Partners on Rhythm Pharmaceuticals (RYTM): CHMP's positive opinion, language shows potential for broad EU labeling
Tweet Send to a Friend
Leerink Partners analyst Thomas J. Smith reiterated an Outperform rating and $142.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
